https://www.epiphanyrx.com/wp-content/uploads/2023/02/Untitled-1-1.png

Discover a better way to manage pharmacy benefits

We Believe

PBMs should make 100% of their revenue from fees paid directly by their clients. This alignment of financial interests is essential to managing costs.

Coverage should be based on lowest net cost and value, not on rebate maximization or optimizing the profits of the PBM-owned pharmacy.

Full visibility of performance metrics is a critical foundation to holding the PBM accountable.

 

mom holding son

WE'RE NOT FOR EVERYONE

Just those who want more from their pharmacy benefits.

Fully aligned, value-based, transparent benefits are possible – for PBMs willing to use them, and for employers that insist on them.

Discover how EpiphanyRx is providing significant, ongoing savings for our clients in a way that no one else does.

EXPLORE MORE
man with arms crossed in lab coat and glasses

WE'RE BREAKING THE TRADITIONAL PBM MOLD

We are removing the conflicts of interest that limit traditional PBMs.

We replace spread pricing, rebate retention and pharmacy ownership with an aligned, transparent business model focused on the lowest net cost and overall value for our clients.

EXPLORE MORE
running a race
Alignment
female pharmacist smiling
Transparency
Real Savings
team meeting
Value-Based Coverage
hugging group

News & Insights

The Fast Five: What’s all the Buzz about Biosimilars? 

Biosimilars are a hot topic in the pharmacy industry right now. Wondering what all the buzz is about?   In this Fast Five, we asked our clinical experts, Janelle Sheen and Imke Scheepers, to share the basics about biosimilars as well as some key insights on this topic.  

The Fast Five: What’s all the Buzz about Biosimilars? 
The Fast Five: Beyond Transparency

Our Vice President of Sales, Jonathan Har-Even, shares his outlook on the industry and where we need to go next. He discusses 5 ways the PBM industry can continue to improve and promote better healthcare for all, including a 5-year plan that uses lowest net cost as a foundation and builds out a platform for payors, members, and pharmacists.

The Fast Five: Beyond Transparency
The Headwinds of Specialty Drug Management

Check out this insightful article published in JMCP on these challenges and the implications for plan sponsors working for a sustainable drug benefit.

The Headwinds of Specialty Drug Management
Information Disadvantages Created by PBMs

Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.

Information Disadvantages Created by PBMs
Challenges with Ineffective PBM Clinical Management for Specialty Drugs

Is your PBM applying rigorous clinical criteria to effectively identify and remove waste in your specialty drug benefit?  Learn how misaligned coverage models and weak clinical criteria are working against plan sponsors. This white paper is the second of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.

Challenges with Ineffective PBM Clinical Management for Specialty Drugs
PBM Conflicting Financial Interests in Managing Specialty Drugs

Are your PBM's financial interests fully aligned with yours? Learn more about the inherent financial conflicts found in traditional PBM business models. This white paper is the first of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.

PBM Conflicting Financial Interests in Managing Specialty Drugs
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×